Cargando…

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine. [Corrigendum]

Detalles Bibliográficos
Autores principales:	Nanda, K, Moss, AC
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794659/ https://www.ncbi.nlm.nih.gov/pubmed/23378789 http://dx.doi.org/10.2147/CPAA.S42466

Ejemplares similares

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine
por: Nanda, Kavinderjit, et al.
Publicado: (2012)

Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis
por: Kedia, Prashant, et al.
Publicado: (2007)

Patient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine
por: Zandman, Daniel B, et al.
Publicado: (2009)

The relationship among multiple patient-reported outcomes measures for patients with ulcerative colitis receiving treatment with MMX(®) formulated delayed-release mesalamine
por: Yarlas, Aaron, et al.
Publicado: (2014)

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
por: Kamm, M A, et al.
Publicado: (2008)

The role of mesalamine in the treatment of ulcerative colitis
por: Karagozian, Raffi, et al.
Publicado: (2007)

Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease
por: Doherty, Glen A, et al.
Publicado: (2009)

Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety
por: Maconi, Giovanni, et al.
Publicado: (2021)

Retrospective investigation of mesalamine intolerance in patients with ulcerative colitis
por: Minagawa, Yuki, et al.
Publicado: (2022)

Effectiveness of Mesalamine in Patients With Ulcerative Colitis: A Systematic Review
por: Santos, Yurianna, et al.
Publicado: (2023)

Corrigendum to “A Rare Case of New-Onset Ulcerative Colitis following Initiation of Secukinumab”
por: Achufusi, Ted George, et al.
Publicado: (2019)

Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis
por: Lichtenstein, Gary R., et al.
Publicado: (2015)

Kangfuxinye Enema Combined with Mesalamine for Ulcerative Colitis: A Systematic Review and GRADE Approach
por: Ren, Peng-wei, et al.
Publicado: (2017)

Effect of MMX(®) mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials
por: Pierce, David, et al.
Publicado: (2014)

Corrigendum to: Association between matrix Gla protein and ulcerative colitis according to DNA microarray data
por: Dong, Xu-Yang, et al.
Publicado: (2020)

Corrigendum to: Providing Hospitalized Ulcerative Colitis Patients With Practice Guidelines Improves Patient-Reported Outcomes
Publicado: (2020)

Myocarditis Secondary to Mesalamine-Induced Cardiotoxicity in a Patient with Ulcerative Colitis
por: Okoro, Kelechukwu U., et al.
Publicado: (2018)

Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies
por: Panés, Julian, et al.
Publicado: (2019)

Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
por: Yagisawa, Keiji, et al.
Publicado: (2020)

Corrigendum: Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial
por: Rubin, David T, et al.
Publicado: (2017)

Exacerbation of Bloody Diarrhea as a Side Effect of Mesalamine Treatment of Active Ulcerative Colitis
por: Shimodate, Yuichi, et al.
Publicado: (2011)

Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis
por: Cuffari, Carmen, et al.
Publicado: (2016)

Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine
por: Oliveira, Lilliana, et al.
Publicado: (2011)

Genetic variants in cellular transport do not affect mesalamine response in ulcerative colitis
por: Moran, Christopher J., et al.
Publicado: (2018)

A Case of Right-Sided Ulcerative Colitis with Mesalamine-Induced Hypersensitivity Reactions
por: Hirono, Haruka, et al.
Publicado: (2018)

Urine Discoloration After Voiding in a Boy With Ulcerative Colitis Using Mesalamine
por: Zeef, Dagmar, et al.
Publicado: (2022)

Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: A double-blind, randomized study
por: Ito, Hiroaki, et al.
Publicado: (2010)

Corrigendum: Unmet Psychosocial Needs of Patients Newly Diagnosed with Ulcerative Colitis: Results from the Nationwide Prospective Cohort Study in Korea
por: Moon, Jung Rock, et al.
Publicado: (2021)

A Case of Stevens–Johnson Syndrome Complicated with Multimatrix System Mesalamine in Ulcerative Colitis
por: Kanazawa, Mimari, et al.
Publicado: (2022)

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study
por: Travis, Simon P L, et al.
Publicado: (2014)

Corrigendum to: Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis
por: Kierkus, Jaroslaw, et al.
Publicado: (2020)

Gut Microbiota and Related Metabolites Were Disturbed in Ulcerative Colitis and Partly Restored After Mesalamine Treatment
por: Dai, Liang, et al.
Publicado: (2021)

Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management [Corrigendum]
Publicado: (2022)

Fulminant organizing pneumonia in a patient with ulcerative colitis on mesalamine and infliximab: striving to identify the cause!
por: Gomes, Lídia, et al.
Publicado: (2023)

Fixed combination of lercanidipine and enalapril in the management of hypertension; focus on patient preference and adherence [Corrigendum]
Publicado: (2013)

Guideline development for the management of gout: role of combination therapy with a focus on lesinurad [Corrigendum]
Publicado: (2017)

Smoking cessation in Asians: focus on varenicline [Corrigendum]
Publicado: (2015)

Extraglottic airway devices: technology update [Corrigendum]
Publicado: (2018)

Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study
por: Danese, Silvio, et al.
Publicado: (2016)

Corrigendum: Table and Text Correction. Recent Updates on Type 1 Diabetes Mellitus Management for Clinicians
por: Iqbal, Ahmed, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ro43f7faoqi8n6lehmn5a8ivse